S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
Log in
NASDAQ:GBSN

(GBSN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.11
0.00 (0.00 %)
(As of 03/6/2018)
Add
Today's Range
$0.10
Now: $0.11
$0.12
50-Day Range N/A
52-Week Range
$0.03
Now: $0.11
$18.00
Volume104,097 shs
Average Volume99,205 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.
(GBSN) logo

Headlines

Monitor glacial lakes
September 8, 2020 |  msn.com
What's behind Trump's bizarre suggestion
August 2, 2020 |  www.msn.com
See More Headlines

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:GBSN
CUSIPN/A
Phone+1-801-9901055
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive GBSN News and Ratings via Email

Sign-up to receive the latest news and ratings for GBSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











(GBSN) (NASDAQ:GBSN) Frequently Asked Questions

What stocks does MarketBeat like better than (GBSN)?

Wall Street analysts have given (GBSN) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (GBSN) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were (GBSN)'s earnings last quarter?

(GBSN) (NASDAQ:GBSN) released its earnings results on Wednesday, March, 22nd. The medical research company reported ($18.25) earnings per share for the quarter. The medical research company earned $0.85 million during the quarter.
View (GBSN)'s earnings history
.

When did (GBSN)'s stock split? How did (GBSN)'s stock split work?

(GBSN)'s stock reverse split before market open on Friday, September 16th 2016. The 1-80 reverse split was announced on Wednesday, September 14th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 15th 2016. An investor that had 100 shares of (GBSN) stock prior to the reverse split would have 1 shares after the split.

Who are (GBSN)'s key executives?

(GBSN)'s management team includes the following people:
  • David Spafford, Executive Chairman of the Board (Age 55)
  • Robert Jenison, Senior Vice President - Research, Chief Technology Officer (Age 50)
  • Ryan Ashton, President, Chief Executive Officer, Director (Age 56)
  • Kirk K. Calhoun, Independent Director (Age 73)
  • Sam Chawla, Independent Director (Age 41)
  • Ronald K. Labrum, Independent Director (Age 60)

What other stocks do shareholders of (GBSN) own?

What is (GBSN)'s stock symbol?

(GBSN) trades on the NASDAQ under the ticker symbol "GBSN."

What is (GBSN)'s stock price today?

One share of GBSN stock can currently be purchased for approximately $0.11.

What is (GBSN)'s official website?

The official website for (GBSN) is gbscience.com.

Where are (GBSN)'s headquarters?

(GBSN) is headquartered at 420 E South Temple Ste 520, SALT LAKE CITY, UT 84111-1362, United States.

How can I contact (GBSN)?

(GBSN)'s mailing address is 420 E South Temple Ste 520, SALT LAKE CITY, UT 84111-1362, United States. The medical research company can be reached via phone at +1-801-9901055.


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.